C07K 2319/31
Fusions, other than fc, for prolonged plasma life
Official title: fusions, other than Fc, for prolonged plasma life, e.g. albumin
C07K2319/31 (Fusions, other than fc, for prolonged plasma life) appears on 898 US grants and 1,784 published applications in this corpus.
Search patents in C07K- Granted patents
- 898
- Published applications
- 1,784
- Assignees
- 616
- Inventors
- 2,886
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 4 | 0 |
| 2000 | 3 | 0 |
| 2001 | 0 | 1 |
| 2002 | 3 | 5 |
| 2003 | 1 | 14 |
| 2004 | 1 | 7 |
| 2005 | 5 | 12 |
| 2006 | 9 | 17 |
| 2007 | 3 | 26 |
| 2008 | 3 | 31 |
| 2009 | 8 | 38 |
| 2010 | 15 | 45 |
| 2011 | 16 | 51 |
| 2012 | 21 | 54 |
| 2013 | 26 | 72 |
| 2014 | 36 | 75 |
| 2015 | 44 | 81 |
| 2016 | 56 | 119 |
| 2017 | 56 | 88 |
| 2018 | 65 | 100 |
| 2019 | 60 | 98 |
| 2020 | 69 | 118 |
| 2021 | 81 | 141 |
| 2022 | 70 | 130 |
| 2023 | 51 | 120 |
| 2024 | 68 | 142 |
| 2025 | 74 | 122 |
| 2026 | 48 | 77 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Fusion polypeptide and polypeptide dimer, and use thereof29 Sep 2026US 12,747,275 B2Nanjing Normal University
- Ulinastatin polypeptides8 Sep 2026US 12,729,233 B2DiaMedica USA Inc.
- Hydrophilic linkers for antibody or DARPin conjugates8 Sep 2026US 12,729,236 B2Valitor, Inc.
- Method of increasing an immune response to a cancer by administering an antibody which inhibits erythropoietin receptor activation8 Sep 2026US 12,729,240 B2ImmunEdge, Inc.
- Immunoglobulin variable domains1 Sep 2026US 12,723,072 B2Ablynx N. V.
- Antibody binding to il-18 receptor, il-18 receptor activator, and use thereof24 Sep 2026US 2026/0285989 A1Wio Bioscience Co., Ltd.
- Engineered il-21 variants and methods of use thereof17 Sep 2026US 2026/0274912 A1FBD Biologics Limited
- Interleukin-33 variants, compositions and uses thereof10 Sep 2026US 2026/0265325 A1Slate Bio, Inc.
- Conditionally activated receptor signaling by using scaffold protein10 Sep 2026US 2026/0265386 A1
- Low-cost cell-free insulin based on self amplifying rna10 Sep 2026US 2026/0265802 A1DEI Biopharma
Most cited
By later US patents
- Fusion polypeptides comprising human serum albumin, nucleic acids encoding same, and recombinant expression thereof208US 5,876,969 A1999
- Albumin fusion proteins comprising GLP-1 polypeptides198US 7,141,547 B2Human Genome Sciences, Inc. · 2006
- GLP-1 fusion proteins165US 7,271,149 B2Eli Lilly and Company · 2007
- Albumin fusion proteins157US 6,905,688 B2Human Genome Sciences, Inc. · 2005
- Fusion polypeptides of human serum albumin and a therapeutically active polypeptide136US 6,686,179 B2Aventis Behring GmbH · 2004